New combo therapy shows promise for leukemia patients
NCT ID NCT02201459
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tested whether adding pegylated interferon to the standard drug nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response. About 200 adults under 65 took either nilotinib alone or nilotinib plus the added drug for up to 24 months. The main goal was to see how many patients reached a very low level of cancer cells (MR4.5) after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Franck NICOLINI
Lyon, 04 78 86 22 50, France
Conditions
Explore the condition pages connected to this study.